Search results
monal contraceptives (HC) in breast cancer risk. This analysis used nationwide Danish registries to identify breast cancer cases among girls and women aged 15-49 years and filled prescriptions for HC (including the levonorgestrel-intrauterine system [LNG-IUS]).
7 gru 2017 · The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1...
23 wrz 2022 · Overall, 54.2% of patients reported contraceptive use at the time of breast cancer diagnosis, but a significant decrease in use was observed during primary treatment (year 1) and follow-up (year 2).
This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
Intrauterine devices (IUDs) may raise the chances of a breast cancer diagnosis for women who use the hormonal birth control method, but that risk remains low, new research finds.
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
6 dni temu · During follow-up of almost 7 years, hormone-releasing IUD use conferred a 40% higher risk of breast cancer. The data showed a trend toward increasing risk with duration of IUD use,...
